[NASDAQ: LSMT] BASEL // BOSTON // ZURICH CLINICAL LABS
CAS12 ACCURACY RATING: 99.988%
// PRECISION MOLECULAR MEDICINE

Programming the fundamental
architecture of human life.

Life Sciences & Molecular Therapeutics (LSMT) pioneers targeted genetic interventions and precision synthetic gene circuits. By combining AI-driven protein folding models with ultra-stable lipid nanoparticle vectors, we eradicate complex cellular disease at its root code.

Vector Synthesis Telemetry
SEQ_ID: CRISPR-LSMT9
Codon Stability Index OPTIMIZED (99.4%)
Target Binding EXON-14 CLEAVED
Delivery Vector LNP-TARGETED
> SYNTHESIZING mRNA PAYLOAD... DONE
> MAPPING CELLULAR RECEPTOR KINETICS
> ZERO OFF-TARGET MUTATIONS DETECTED.
// CLINICAL FOCUS

Redefining modern therapeutics.

01 // GENE EDITING VECTORS

Next-Gen CRISPR Modalities

Engineering proprietary engineered nucleases that correct single-nucleotide polymorphisms in vivo with absolute single-base precision, avoiding chromosomal toxicity.

02 // SYNTHETIC mRNA

Custom Peptide Translation

Developing circular RNA (circRNA) architectures that dramatically extend protein translation half-life inside target tissues for sustained therapeutic efficacy.

03 // COMPUTATIONAL BIOLOGY

AI Protein Engineering

Utilizing deep neural networks trained on millions of molecular interactions to design entirely de novo proteins that neutralize previously undruggable oncogenic targets.